By Sara Calabro
On Thursday, the FDA recommended to reverse the approval of Avastin for breast cancer, a decision that The Washington Post says, “intensifies a politically charged debate over costly cancer drugs that appear to produce modest benefits—if any.” It also raises questions about the research processes by which therapies, including acupuncture, are deemed effective.
In a case of crystal-ball reporting, The New Yorker, three days before the Avastin news broke, covered the “decline effect” in research. This refers to the increasingly common phenomenon of follow-up studies failing to confirm original research findings. Avastin gained approval for breast cancer in 2008, based on one study that showed it slowed the growth of breast tumors. The FDA signed off with the understanding that the drug’s maker would conduct follow-up studies to confirm the results. Those studies proved unimpressive. Keep reading